Investors See Big Opportunity in AI

Artificial Intelligence could be the next big market in medtech that investors flock to. Earlier this week, Viz.ai proved that this might just be the case as it raised about $21 million in a series A round. The round was led by Kleiner Perkins, with participation from GV, formerly Google Ventures. “One of the things we’re going to use the money is to expand beyond stroke and provide value to our hospitals, partners, and customers,” Chris Mansi, co-founder and CEO of Viz.ai., told MD+DI. “The second thing we’re going to use the money for is to ensure that more hospitals get access to our software.” Worldwide, more than six million stroke-related deaths occur every year and strokes are the number one cause of long-term disability in the nation. Outcomes are predicated on timely diagnosis and early access to neurological specialists. The San Francisco, CA-based company received a de novo FDA clearance back in February for its Contact Application to analyze CT results that could notify providers of a potential stroke in their patients. Viz.ai changed the name of Contact Application to Viz LVO. The company also received clearance for the Viz CTP in April. The application offers providers an important tool for automated cerebral image analysis. Mansi said AI technology is beginning to capture a lot of attention and it has the potential to serve a real need in healthcare. “I think there is a lot of excitement in [AI],” Mansi said. “Several things have come togethe...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Digital Health Source Type: news